Background. The occurrence of congenital heart disease (CHD) with congenital biliary disease is uncommon. Our aim is to present our experience in living donor liver transplantation (LDLT) as treatment for end-stage liver disease (ESLD) in children with CHD. Methods. A review of transplant records from June 1994 to December 2004 was performed. Twenty-three LDLT (13 males, 10 females) recipients were diagnosed to have both CHD and ESLD. Results. CHD diagnoses were made preoperatively using transthoracic two-dimensional color flow Doppler echocardiography. The mean age was 22.3 months. There were 20 (87%) biliary atresia, two (9%) neonatal hepatitis, and one (4%) glycogen storage disease patients. Isolated CHD associated with ESLD included atrial septal defect (11, 48%), pulmonary stenosis (including 2 Alagille syndrome; 4, 17%), patent foramen ovale (4, 17%), ventricular septal defect (1, 4%), and mitral valve prolapse (1, 4%). Complex CHD included atrial septal defect ϩ patent ductus arteriosus ϩ patent foramen ovale (1, 4%), and atrial septal defect ϩ pulmonary stenosis (1, 4%). The median Child's and Pediatric End-stage Liver Disease scores were 9, and 17, respectively. In all, 70% presented with varying degrees of pulmonary congestion pretransplant. There were no perioperative cardiac complications. Posttransplant, the patent foramen ovale in four recipients and atrial septal defect in four recipients closed spontaneously; and two recipients with pulmonary stenosis had their stenoses resolved spontaneously. The overall rejection rate was 17%. There was no mortality. The overall recipient and graft survivals at 1 and 5 years were both 100%. Conclusion. LDLT is a safe procedure in a select group of ESLD patients with CHD.
nd-stage liver disease (ESLD) coexisting in patients with congenital heart disease (CHD) is seldom encountered in liver transplantation (LT). This may be due to natural selection where one condition prevails over the other at presentation: either the patient is too sick due to liver disease that it precludes heart surgery or in heart failure, which makes LT exceedingly risky.
Commonly, CHD presents with varying degrees of pulmonary congestion and hypoxemia. The condition may be worsened by liver dysfunction and intrapulmonary vascular dilatation in co-existing liver disease or vice versa. The causes of hypoxemia in advanced liver disease have been attributed to right-to-left intrapulmonary shunting, alveolar-capillary diffusion defect, and alveolar-ventilation mismatch (1) . As such, the management of patients with ESLD with co-existing CHD poses both diagnostic and therapeutic challenges for clinicians. Depending on the severity of the cardiac condition, clinicians often argue that these types of patients may not tolerate LT to survive.
The impact and outcome of hemodynamically insignificant heart disease in children undergoing LT and the outcome of LT remain to be elucidated. Our objective is to present our experience in managing these types of patients as they receive living donor liver transplantation (LDLT) to solve the preexisting liver disease. The approaches, advantages, and pitfalls in the management are described.
PATIENTS AND METHODS
From June 1994 to December 2004, 203 LDLT were performed at the Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan. Twenty-three (11%) patients were diagnosed with both ESLD and CHD. All CHD diagnoses were detected preoperatively by transthoracic two-dimensional color flow Doppler echocardiography (2-D echo). The records of these patients were retrospectively analyzed as well as their follow-up.
Cardiac Evaluation
A transthoracic 2-D echo (Philips, Andover, MA) was performed at least twice before the recipients underwent LT to validate the presence of a CHD and structural abnormalities. If necessary, a cardiac catheterization was made available for further evaluation of the cardiac anomaly and hemodynamic status. A comanagement with a pediatric cardiologist was made perioperatively and at follow-up. A repeat transthoracic 2-D echo was done at least 3 months after transplant to the latest follow-up date.
Operative Technique and Anesthesia Management
Our techniques of donor left graft hepatectomy and recipient total hepatectomy in LDLT have been described in detail previously (2, 3) . The graft consisted of either the left lateral segment (segments 2, 3) or an extended left lateral segment (segments 2, 3, part of 4). Triple recipient venoplasty consisting of septal division of intervening septa between right, middle, and left hepatic veins and trimming of redundant edges was done. Assuring the correct orientation of the graft and recipient vessels, the graft hepatic vein was anastomosed to recipient hepatic vein triple venoplasty opening with the inferior vena cava cross-clamped. Venovenous bypass was not used. The graft was reperfused after portal vein anastomosis followed by hepatic artery reconstruction under microsurgical techniques. Extreme care to prevent air and particulate embolism in the cava was done by flushing the graft with cold lactated Ringer's solution before completion of hepatic vein and portal anastomoses. Biliary reconstruction was completed and the falciform ligament was reconstructed. Intraoperative Doppler ultrasound was performed to check vascular flow patterns and velocities after vascular reconstructions, and before and after abdominal closure.
The anesthesia management was as protocol by the Department of Anesthesiology (4) . Red blood cell transfusion was not given for hemoglobin higher than 8.0 g/dL and as long as the intravascular volume was sufficient to maintain normal hemodynamic.
Immunosuppression
Immunosuppression was as protocol using cyclosporine (Novartis, Basel, Switzerland), azathioprine (GlaxoWellcome, Auckland, New Zealand), and steroid. All recipients received tapered prednisone for a minimum of 3 months. All rejections were biopsy-proven and managed with intravenous pulse methylprednisolone (10 mg/kg/body weight) and/or an increase in the dose of the current immunosuppression (5).
Data Analyses
Demographic data, form of congenital heart disease, type of liver disease, donor-recipient characteristics, complications, and outcome were analyzed. Data were presented as mean and median as appropriate. SPSS Advanced Module Statistic (SPSS, Chicago, IL) was used to analyze data. MannWhitney test was used to analyze relationships between the presence of CHD, age and recipient extubation. A P value Ͻ0.05 was considered significant. Kaplan-Meier curves were used to measure survival.
RESULTS
All 23 patients diagnosed to have both CHD and ESLD were recommended to undergo LT. There were 13 male and 10 female patients. The overall mean age was 22.3 months (range, 8 -120) . For males, the mean age was 29 months, whereas for females it was 17 months. The overall mean preLT weight was 8.7 kg. There were 20 (87%) biliary atresia (BA), two (9%) neonatal hepatitis (NH), and one (4%) glycogen storage disease patients. Isolated CHD associated with ESLD included: 11 atrial septal defect (ASD; 48%), four pulmonary stenosis (PS, including two Alagille syndrome; 17%), four patent foramen ovale (PFO; 17%), one ventricular septal defect (VSD; 4%), and one mitral valve prolapse (4%). Complex CHD included one case of ASDϩPDAϩPFO (4%) and one case of ASDϩPS (4%). The median Child-TurcottePugh score was 9 and Pediatric Model for End-stage Liver Disease was 17. Eighteen BA patients underwent Kasai operation prior to transplant. The two NH patients underwent laparotomy, intraoperative cholangiography, and liver biopsy before they were referred for LT. Although 70% of the patients presented with varying degrees of pulmonary congestion, no patient presented with heart failure symptoms. Likewise, no patient presented with cyanosis. Table 1 summarized the patients' demographics and clinical characteristics.
One patient (LDLT 183) with ASD showed cardiomegaly on chest radiograph and electrocardiogram tracings suggestive of right axis deviation and right ventricular hypertrophy. The transthoracic 2-D echo in this patient revealed a significantly dilated right atrium and right ventricle but the patient was asymptomatic. The same patient subsequently underwent cardiac catheterization which revealed a pulmonary blood flow to systemic blood flow ratio of Ͼ1.5 (normal: Ͻ1.5), an indication for ASD closure. A thorough pretransplant discussion was made with the surgeons and hospital ethics committee regarding the indications for transplant and whether which operation should be done first: LT to correct the liver failure problem or heart surgery to address the heart condition. Since the patient was judged to be asymptomatic or heart failure symptom-free and the heart problem was based only on significant values appreciated on diagnostic imaging, it was decided to treat the patient clinically and to go ahead with the transplant operation.
One Alagille syndrome patient underwent balloon angioplasty of the pulmonary arteries before transplant. Cardiac catheterization was not indicated in the remaining patients and did not require cardiac drug support perioperatively.
Operative Outcomes
Of the 23 recipients, 87% (20) received left lateral segment grafts and 13% (3) received extended left lateral segment grafts. Seventeen percent of the recipients did not require intraoperative blood transfusion. Venovenous bypass was not used in any recipient. Seven left-side grafts underwent graft hepatic vein venoplasty at backtable (LHVϩLSV; LHVϩV3 vein) before anastomosis with the recipient hepatic vein. One patient developed both hepatic outflow insufficiency and hepatic artery thrombosis which were detected intraoperatively by routine use of Doppler ultrasound after vascular reconstruction. Redo hepatic artery anastomosis was done and the hepatic outflow problem due to graft malpositioning was managed by application of a Foley catheter into the right subhepatic space (6) . There were no other complications related to vascular and biliary anastomoses. There was no reoperation or hospital mortality in the recipients. 
Congenital Heart Disease Outcomes
Four patients with isolated ASD had their ASD closed spontaneously while awaiting transplant, whereas another four patients with isolated ASD had spontaneous ASD closure posttransplant. Two patients (LDLT 32,183) with ASD had an increase in the size of their ASD, whereas one patient (LDLT 42) had a decrease in ASD size on subsequent follow-up after transplant. In one patient with both ASD and VSD (LDLT 120), the ASD closed before transplant while the VSD persisted after transplant. In another patient with ASD, PDA, and PFO (LDLT 142), the ASD and PDA closed spontaneously pretransplant and the PFO closed spontaneously posttransplant. All PFO closed spontaneously after transplant. Two patients with isolated PS had their PS resolved spontaneously after transplant. Mild PS persisted in the two Alagille syndrome patients posttransplant. One patient (LDLT 183) underwent Amplatzer septal occluder closure of the ASD 10 months posttransplant due to development of heart failure symptom and increase in ASD size. Table 1 summarizes the preoperative and latest 2-D echo findings.
There was no perioperative cardiac complication. Arrhythmias and signs of a right-sided heart failure were not noted before or after reperfusion during the operation and in the intensive care unit. Likewise, there was no episode of hypotension or desaturation. Intraoperative transesophageal echocardiography during the transplant operation was not necessary in any patient. There were no neurologic deficits noted which may be attributed to particulate or air embolism crossing the septal defect to the systemic circulation during the early and late posttransplant period in patients with cardiac septal anomaly.
When we compared these 23 CHD-ESLD recipients with 90 pediatric recipients without CHD who underwent LDLT, the CHD-ESLD recipients were younger (mean ages, 22.3 months vs. 43.44 months; Pϭ0.033). Despite the significant difference in age, there was no significant difference in their length of intubation postLDLT (CHD 20 hr vs. non-CHD 16 hr; Pϭ0.791). There were no significant relationships between the presence of CHD, recipient age, and length of intubation postLDLT in this series.
Follow-up and Survival
The overall rejection rate was 17% (three moderate and one mild). All rejections were biopsy proven, and managed successfully by intravenous pulse methylprednisolone. The mean follow-up was 50.7 months (range, 19.8 -99.4). All recipients were surviving with their original graft. The overall actuarial patient and graft survivals at 1 year and 5 years were all 100%.
DISCUSSION
The association of congenital biliary disease and CHD has often been described as syndromic. BA, though rarely associated with other congenital anomalies (7), is associated with CHD in about 12% of cases (8) . BA is also the most common indication for LT in children. In 1987, Cziezel (9) found an association between VSD and extrahepatic biliary atresia (EHBA), and Alagille syndrome as common manifestations of then newly identified group of congenital anomaly combination named biliary dysgenesis-congenital cardiovascular malformation association. The etiopathogeneses of this association are described to arise from malformation, disruption, chromosome abnormality, and from effects of agents during perinatal period (8) . Peripheral PS with or without intracardiac disease is also described with intrahepatic biliary dysgenesis, and is postulated to be a specific malformation syndrome resulting most probably from intrauterine infection (10) . The more common Alagille syndrome is a genetic autosomal dominant disorder. The severity of biliary dysgenesis often requires LT.
Children with CHD are at an increased perioperative risk during LT due to cardiopulmonary abnormalities and the intrinsic hemodynamic changes associated with the LT operation. Clinicians argue that depending on the degree of severity of cardiovascular disease and/or liver disease, these patients with ESLD needing LT are too sick and will not tolerate the required operation. Several reports have been published attesting to the safety of LT for patients with congenital heart disease, particularly, in Alagille syndrome (11) (12) (13) (14) (15) . Early recognition of the cardiac abnormality and patient preparation are of paramount importance in all the reports.
BA associated with cyanotic CHD causes an atypical green-appearing cutaneous discoloration due to cyanosis and jaundice which mask the early clinical detection of BA or cyanotic heart disease (16) . Awareness of the rare occurrence of combined CHD and BA is helpful to the clinician when evaluating infants with atypical cutaneous discoloration. We have not encountered this form of cutaneous discoloration in our patients.
In contrast to Cziezel's findings that VSD and EHBA are more common findings in biliary dysgenesis-congenital cardiovascular malformation association, we find in this present series ASD and EHBA to be more common. ASD is one of the more common congenital heart defects occurring in 10 -15% of all patients with CHD. Secundum type of ASD, in particular, occurs in 60 -65% of all ASD patients (17) .
In the context of coexisting ESLD, it is difficult to ascertain whether the manifested signs of pulmonary congestion are due to the cardiovascular decompensation or liver disease. ESLD causes hypoalbuminemia, ascites, and jaundice. Hypoalbuminemia as manifested by pulmonary congestion is also seen in decompensated ASD with congestive heart failure. Massive ascites causes severe restrictive ventilatory pattern and hypoxemia mimicking hepatopulmonary syndrome, complicated ASD, or large VSD. Jaundice is also seen in severe congestive heart failure from chronic passive liver congestion. It is crucial, therefore, to identify which condition caused the patient's symptoms that need immediate intervention.
Transthoracic 2-D echo is the most useful noninvasive modality for the detection of intracardiac or intrapulmonary shunts. In patients with septal defects, microbubbles can be seen entering the left heart chamber immediately after their appearance in the right heart chamber, usually in one or two cardiac cycles. On the other hand, in patients with intrapulmonary shunting, microbubbles from the pulmonary veins appear in the left atrium after a delay of at least three cardiac cycles (18) . Cardiac catheterization may be necessary if lesions can not be confirmed by transthoracic or transesophageal 2-D echo.
Lung scan using technitium-99-labeled microaggregate albumin and pulmonary angiography are reliable diagnostic tests for intrapulmonary shunting as seen in hepatopulmonary syndrome. Pulmonary angiography has added value because it can detect pulmonary vascular abnormalities that can have prognostic significance (19) .
Transthoracic 2-D color flow Doppler echocardiography revealed that the CHD cases described in this series have good left ventricular functions with no signs of decompensated heart failure. These findings helped us decide to proceed with LT as the symptoms were attributable to ESLD.
Patients with septal defects, such as ASD or PFO, who are undergoing vascular surgery are at risk of paradoxical embolus either from air or particulate that enter blood vessels. The embolus passes through the septal defect from the right atrium into the left atrium, then into the left ventricle to the aorta. This paradoxical embolus can cause perioperative stroke. Likewise, postoperatively, embolism entering the cerebral circulation may be manifested as stroke or neurologic deficit. Massive air or particulate in the vena cava may cause pulmonary embolism. Pulmonary embolism should be suspected in any patient who suddenly develops desaturation followed by circulatory collapse after the release of caval clamps. Theoretically, septal defects patients may go into acute right ventricular dysfunction on the operating table due to sudden gush of blood after caval clamp release from an existing left-to-right shunt. Intraoperatively, this right-sided heart failure can be appreciated by sudden and unexplained hypotension in the patient. A right-sided heart failure occurring posttransplant can be manifested as hepatic congestion and may mimic hepatic outflow obstruction. There is increased systemic venous pressure because the right side of the heart cannot pump the blood. This increased systemic venous pressure creates sinusoidal pressure changes in the liver similar to hepatic congestion seen in hepatic vein obstruction. Knowledge of these potential complications should alert the clinician in the postLT intensive care unit for any cardiac, pulmonary, or neurologic abnormalities in addition to problems peculiar to immediate postLT recipients.
This series demonstrated that LT can be safely performed in hemodynamically stable CHD patients as long as the indications for transplantation are clear. Proper patient selection is important. It is worthwhile to note that 21 of 23 patients in these series have had previous operation prior to the transplant procedure. Although with CHD, all recipients are good cardiac-risk patients with good left ventricular functions. This is important because of the hemodynamic changes that occur during inferior vena cava clamping. If the recipient has marginal or decompensated cardiac function prior to transplant, he may not tolerate the controlled tachycardia that follows with hypotension on caval clamping, or the sudden gush of blood due to left-to-right shunt on caval release. Shimotake (20) even suggested that cardiac decompensation affects postoperative biliary excretion in patients with biliary atresia. We believe that decompensated cardiac function patients should have their cardiac function maximized to a point where the patient can tolerate an LT operation and its immediate postoperative period. We have not encountered any pediatric ESLD patient who was turned down for transplantation due to severe congenital cardiac disease. We also have not encountered any ESLD patient with severe congenital cardiac disease referred for LT. One hypothesis is that these patients might have died before the manifestation of the liver disease.
LT leads to the resolution of problems related to hypoalbuminemia, ascites, pulmonary congestion, and hypoxemia in ESLD patients. For patients with coexisting septal defects, the resolution of such problems may have contributed to spontaneous ASD or PFO closure as the described conditions promote left-to-right shunting in a preexisting atrial septal anomaly. Although reports of spontaneous closure of ASD in premature and full-term neonates have been documented (21) , this occurred in CHD patients without preexisting ESLD problems. Some authors even confirm that some secundum type of ASD can still close past the age of 5 years (22) , and that size of the defect play a major role as defects larger than 6 mm are unlikely to close (23) . On the contrary, other authors claim that ASD defect increase in size making spontaneous closure rare (21, 24) . Further evidence is needed to confirm whether these spontaneous septal defect closures may be attributed to the effects of postLT condition or due to natural history. As coexistence of biliary dysgenesis and CHD is uncommon in patients receiving LT, further epidemiologic, etiologic, pathologic, and clinical management studies have to be made on the natural history of this congenital anomaly.
In summary, we have described our experience in treating patients with coexisting CHD and ESLD who underwent successful LDLT. Hemodynamically insignificant structural heart defects did not show a negative impact in the outcome of transplantation. Spontaneous closure of the septal defects in some patients even occurred before and after transplantation. In general, the patients' cardiovascular problem did not worsen after transplantation and did not dramatically increase perioperative risk. Hence, the presence of a compensated CHD in selected patients with ESLD does not preclude LDLT.
